clozapine has been researched along with Attention-Deficit-and-Disruptive-Behavior-Disorders* in 4 studies
2 review(s) available for clozapine and Attention-Deficit-and-Disruptive-Behavior-Disorders
Article | Year |
---|---|
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Atypical antipsychotics offer superior safety and similar efficacy compared with conventional agents in adults with psychotic disorders. Consequently, atypical antipsychotics have been increasingly used in children and adolescents. Because most information now available on pediatric use comes from case reports and small open-label studies rather than large controlled trials, treatment in pediatric patients is often guided by experience with adults or based on limited evidence in youths. Although the literature contains reports on the use of each agent in this class in children, risperidone has been the focus of the greatest number of reports. However, the atypical antipsychotics are not interchangeable; each has a unique pharmacologic profile and may differ considerably in terms of adverse effects. Evidence on the use of atypical antipsychotics in children and adolescents is summarized in this review. Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Child Development Disorders, Pervasive; Clozapine; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Tic Disorders | 2004 |
2 other study(ies) available for clozapine and Attention-Deficit-and-Disruptive-Behavior-Disorders
Article | Year |
---|---|
Clozapine and Electroconvulsive Therapy Is an Effective and Safe Treatment During Pregnancy: A Case Report.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Clozapine; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Electroconvulsive Therapy; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Schizophrenia; Treatment Outcome | 2019 |
Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors.
Autism spectrum disorder (ASD) is a serious childhood-onset disorder in which social and language development are primarily affected, with associated repetitive behavior and, in some patients, behavioral symptoms including aggression and self-injury. In ASD, risperidone and aripiprazole are the only second-generation antipsychotic drugs that have shown to decrease disruptive behaviors in large-scale, controlled, double-blind studies. However, in some patients, these medications are not effective. Clozapine, a second-generation antipsychotic drug known to be effective in the treatment of aggression associated with schizophrenia, has received little attention in ASD.We conducted a retrospective analysis of the changes in disruptive behaviors for all patients with ASD treated with clozapine from 2002 to 2010. Disruptive behaviors were monitored during the 4 to 6 months before and after the initiation of clozapine. Long-term tolerance (10 months to 7 years) was also assessed. The relationship between disruptive behaviors and period of treatment (before and after clozapine) was studied with a generalized linear marginal model. Clozapine resulted in a significant 2-fold decrease in the number of the days with aggression, a decrease in the number of psychotropic drugs, and a decrease in the dose of the antipsychotic drugs. The long-term tolerance of clozapine (white blood cell count and extrapyramidal effects) was good, with the exception of significant weight gain (14.3 ± 10.9 kg), the occurrence of metabolic syndrome in 1 patient, and tachycardia in another patient.These results suggest that clozapine should be considered for the management of disruptive behaviors in patients with ASD not improved by first-line antipsychotic drugs. Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Female; Humans; Male; Psychiatric Status Rating Scales; Retrospective Studies | 2011 |